Available technologies

Serum test to differentiate Sarcoidosis from Tuberculosis

Reference number: 8033

Blood cells artery vein circulation light vessel

Background

Pulmonary Sarcoidosis (SA) is a chronic inflammatory disease with no known aetiology that often results in a skin rash, shortness of breath and a persistent cough. A major clinical problem in hospitals is the diagnosis of sarcoidosis because the disease shares symptomatic, radiological and immune-pathological features with the more common disease, Tuberculosis (TB), which results from infection by Mycobacterium tuberculosis and affects a third of the world’s population. As Sarcoidosis is unresponsive to Tuberculosis therapy, a rapid and affordable diagnostic test which could discriminate between the two conditions would dramatically improve time to diagnosis and treatment for individuals with either condition.

Quick Info
  • A current clinical challenge is to differentiate between SA and TB
  • Serum proteomic profiles may hold the key
  • A novel highly specific SA biomarker, CSFR1, has been identified
  • In-patient ratios of CSFR1:S100A8/A9 (SA:TB biomarkers) provide high diagnostic accuracy
  • A simple ELISA-based test has been developed and validated

Technology

  • Using high-resolution mass spectrometry, the inventors quantitatively assessed serum profiles of people suffering from pulmonary forms of both SA and TB
  • Proteomic screening identified 5 proteins that were statistically significant in SA and 122 in TB
  • The protein CSF1R was found to be highly specific to SA and has not been reported as a serum marker for SA previously
  • The in-patient ratio of SA biomarker (CSF1R) and TB biomarker (S100A8/A9) provided high diagnostic accuracy when explored by ELISA methods (AUC = 0.96) (Fig. 1a)
  • A simple ELISA-based test has been developed that correlates well with MS data (Fig. 1b)
  • This method appears to be more sensitive compared to transcriptomic signatures from whole blood
  • The CSFR1/S100A8/A9 marker pair shows better differentiation when compared to a pair of markers composed of a known sarcoidosis marker (Chitotriosidase-1) and a known tuberculosis marker (Matrix metalloproteinase-9).

Download the datasheet

contact

Monika Kraszewska-Hamilton

Healthcare Licensing Executive

monika.hamilton@imperialinnovations.co.uk

Subscribe for Licensing Opportunities updates
Keep up to date with new technologies and licensing opportunities coming out of Imperial College London